Drug class
Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor; targeted antineoplastic
Mechanism of action
Selectively and irreversibly inhibits mutant EGFR, including sensitising mutations and T790M resistance mutation, reducing downstream oncogenic signalling in EGFR-mutated tumour cells.
General use cases
- Treatment of locally advanced or metastatic EGFR-mutated non-small-cell lung cancer (NSCLC) in China and other jurisdictions where aumolertinib is authorised; treatment line and mutation criteria are product- and jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
